Bausch Lomb To Buy XIIDRA Eye Drop From Novartis In Up To $2.5 Bln Deal; Stock Up In Premarket

Eye healthcare firm Bausch + Lomb Corp. (BLCO) Friday said it has entered into a definitive agreement to buy XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop, from Swiss drug major Novartis AG (NVS) for up to $2.5 billion.

from RTT - Before the Bell https://ift.tt/zq28Wwr
via IFTTT